Trial Profile
SFX-01 After Subarachnoid Haemorrhage
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sulforafan (Primary) ; Sulforafan (Primary)
- Indications Subarachnoid haemorrhage
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms SAS
- Sponsors Evgen Pharma
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.
- 16 Jul 2019 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.
- 16 Jul 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2019.